Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 12/20 | 1.00 |
| ▸ | PARP10 | Q53GL7 | 10/20 | 1.00 |
| ▸ | PARP11 | Q9NR21 | 9/20 | 1.00 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL831538 | 1.00 | PARP1 (1.00) | PARP1PARP10PARP11PDPK1ACHE | |
| SCHEMBL30331787 | 0.81 | PARP1 (0.68) | PARP1PARP10PARP11ACHE | |
| SCHEMBL9475196 | 0.81 | PARP1 (0.68) | PARP1PARP10PARP11ACHE | |
| SCHEMBL7582290 | 0.79 | PARP1 (0.65) | PARP1PARP10PARP11PDPK1ACHE | |
| SCHEMBL797996 | 0.78 | PARP1 (0.64) | PARP1PARP10PARP11PDPK1ACHE | |
| SCHEMBL5073463 | 0.78 | PARP1 (0.64) | PARP1PARP10PARP11PDPK1ACHE | |
| SCHEMBL9447443 | 0.78 | PARP1 (0.64) | PARP1PARP10PARP11ACHE | |
| SCHEMBL6421827 | 0.78 | PARP1 (0.64) | PARP1PARP10PARP11PDPK1ACHE | |
| SCHEMBL830807 | 0.78 | PARP1 (1.00) | PARP1PARP10PARP11PDPK1ACHE | |
| SCHEMBL8118685 | 0.78 | PARP1 (0.64) | PARP1PARP10PARP11PDPK1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4419094-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | Edison Oncology (US) | 2024-08-28 | — | — | EP | claimed |
| WO-2023069727-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | EDISON ONCOLOGY (US) | 2023-04-27 | — | — | WO | claimed |
| EP-4694883-A2 | COMBINATIONS COMPRISING AN ATR INHIBITOR AND A PARP INHIBITOR AND METHODS OF USE THEREOF | Jazz Pharmaceuticals Therapeutics, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250381221-A1 | Compositions and Methods for Treating Cancer | IN8BIO INC (US) | 2025-12-18 | — | — | US | disclosed |
| EP-4282490-B1 | FIBRONECTIN-BINDING PEPTIDES FOR USE IN TUMOR OR FIBROSIS DIAGNOSIS AND THERAPY | ETH ZUERICH (CH) | 2025-11-12 | — | — | EP | disclosed |
| US-20250243486-A1 | COMPOSITIONS AND METHODS FOR INHIBITING STAG1 EXPRESSION AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-07-31 | — | — | US | disclosed |
| EP-4554683-A2 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | Lantern Pharma Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| US-20250120963-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF THROMBOCYTOPENIA | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-04-17 | — | — | US | disclosed |
| WO-2025019344-A2 | COMBINATIONS COMPRISING AN ATR INHIBITOR AND A PARP INHIBITOR AND METHODS OF USE THEREOF | Jazz Pharmaceuticals, Inc. (US) | 2025-01-23 | — | — | WO | disclosed |
| EP-4469597-A1 | COMPOSITIONS AND METHODS FOR INHIBITING STAG1 EXPRESSION AND USES THEREOF | President And Fellows Of Harvard College (US) | 2024-12-04 | — | — | EP | disclosed |
| EP-4419094-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | Edison Oncology (US) | 2024-08-28 | — | — | EP | disclosed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2023147400-A1 | COMPOSITIONS AND METHODS FOR INHIBITING STAG1 EXPRESSION AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023104794-A1 | LINKER TECHNOLOGY FOR REDUCED RENAL RETENTION | PAUL SCHERRER INSTITUT (CH) | 2023-06-15 | — | — | WO | disclosed |
| US-11649268-B2 | Fibronectin-binding peptides for use in tumor or fibrosis diagnosis and therapy | ETH ZURICH (CH) | 2023-05-16 | — | — | US | disclosed |
| WO-2023069727-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | EDISON ONCOLOGY (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023057034-A1 | FIBRONECTIN-BINDING PEPTIDES FOR USE IN TUMOR OR FIBROSIS DIAGNOSIS AND THERAPY | ETH Zürich (CH) | 2023-04-13 | — | — | WO | disclosed |
| WO-2023010119-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | LANTERN PHARMA INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| US-20220339179-A1 | TREATMENT OF HR DEFICIENT CANCER | THE FRANCIS CRICK INSTITUTE LIMITED (GB) | 2022-10-27 | — | — | US | disclosed |
| EP-4028009-A1 | TREATMENT OF HR DEFICIENT CANCER | The Francis Crick Institute Limited (GB) | 2022-07-20 | — | — | EP | disclosed |